BioLife Solutions, Inc.
NASDAQ:BLFSMedical - Instruments & Supplies
+$0.40 today
- Market cap
- $1.89B
- Beta
- 1.97
- P/E (TTM)
- -119.9
- EPS (TTM)
- -$0.22
Volume 4.39M
Average 0.52M
BLFS Interest Expense
Cost of servicing the company's debt during the period.
BioLife Solutions, Inc.NASDAQ: BLFS
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense remains negative
Q1 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $660K. Over 3 fiscal years it compounded at +57.9% a year.
Context
- Interest expense amounted to 2.8% of revenue in FY2025, up 1.9 pp from a year earlier.
- Interest expense increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $165K.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 2.71M USD
- Year-over-year change
- +276.4%
- 4-year CAGR
- +53.7%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.71M | +276.4% |
| FY2024 | 2024-12-31 | 719K | -60.3% |
| FY2023 | 2023-12-31 | 1.81M | +163.8% |
| FY2022 | 2022-12-31 | 687K | +41.6% |
| FY2021 | 2021-12-31 | 485K | — |
Interest Expense vs competitors
How BLFS compares with its peers on the latest reported figures
- BLFS's LTM Mar 2026 interest expense of $660K is the 8th highest of the 11 companies compared; the peer median is $7.27M.
- Its year-over-year change of +28.9% is the 2nd highest of 7, against a peer median of +12.0%.
- Interest expense amounts to 0.7% of revenue for BLFS, versus a peer median of 1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $56.45M | -18.7% | +1.0% | 6.4% | |
| LTM Sep 2026 | $28.18M | +17.6% | +29.0% | 10.7% | |
| LTM Mar 2026 | $23.13M | -3.3% | +49.4% | 8.6% | |
| LTM Apr 2026 | $9.32M | +318.3% | +70.2% | 1.9% | |
| LTM Jan 2026 | $7.46M | +6.7% | — | 8.9% | |
| LTM Jun 2026 | $7.07M | +17.3% | +5.6% | 1.2% | |
| LTM Mar 2026 | $2.4M | — | — | 0.4% | |
| LTM Mar 2026 | $660K | +28.9% | +57.9% | 0.7% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Apr 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BLFS) | $7.27M | +12.0% | +29.0% | 1.6% | |
Competitors are the stored peer set for BLFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 119.16M | 76.24M | 75.86M | 82.25M | 96.21M |
| Cost of Revenue | 90.31M | 29.33M | 96.52M | 28.58M | 34.1M |
| Gross Profit | 28.85M | 46.91M | 46.75M | 53.67M | 62.12M |
| Gross Margin | 24.2% | 61.5% | 61.6% | 65.3% | 64.6% |
| Research & Development | 11.82M | 14.8M | 18.8M | 7.91M | 7.57M |
| Selling, General & Admin | 48.09M | 44.93M | 55.97M | 50.15M | 55.37M |
| Operating Expenses | 73.34M | 52.83M | 117.58M | 60.8M | 74.25M |
| Depreciation & Amortization | 12.87M | 19.96M | 12.3M | 8.66M | 4.69M |
| EBITDA | (16.65M) | (124.18M) | (45.24M) | 1.53M | 3.61M |
| EBITDA Margin | -14.0% | -162.9% | -59.6% | 1.9% | 3.7% |
| Operating Income | (35.16M) | (5.92M) | (23.44M) | (7.13M) | (1.08M) |
| Operating Margin | -29.5% | -7.8% | -30.9% | -8.7% | -1.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 485K | 687K | 1.81M | 719K | 2.71M |
| Other Income / Expenses | 6.13M | 1.08M | 4.97M | (4.3M) | (11M) |
| Income Before Tax | (29.03M) | (4.85M) | (18.47M) | (11.43M) | (12.08M) |
| Pre-Tax Margin | -24.4% | -6.4% | -24.4% | -13.9% | -12.6% |
| Income Tax Expense | (20.12M) | (5.24M) | 24K | (38K) | 49K |
| Net Income | (8.91M) | (139.81M) | (66.43M) | (20.18M) | (12.13M) |
| Net Margin | -7.5% | -183.4% | -87.6% | -24.5% | -12.6% |
| EPS (Basic) | (0.23) | (3.29) | (1.52) | (0.44) | (0.25) |
| EPS (Diluted) | (0.23) | (3.29) | (1.52) | (0.44) | (0.25) |
| Weighted Avg Shares | 38.5M | 42.48M | 43.72M | 46.07M | 47.75M |
| Weighted Avg Shares (Diluted) | 38.5M | 42.48M | 43.72M | 46.07M | 48.65M |
BioLife Solutions, Inc.
NASDAQ:BLFS
Intrinsic Alpha fair value
Locked
Current Price
$38.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.